 ALAMEDA, Calif. PITTSBURGH--BUSINESS WIRE--AgeX Therapeutics, Inc. AgeX; NYSE American: AGE, a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. LyGenesis, a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement. The board of directors of AgeX and the board of directors of LyGenesis each determined that it was 